Idarucizumab is administered intravenously, typically in two consecutive doses of 2.5 grams each. The administration is straightforward, allowing rapid onset of action. Healthcare providers should ensure proper hydration and monitor patients for any adverse reactions during and after administration. The dosing regimen is designed to provide effective reversal while minimizing the risk of thrombotic complications.
